Next Article in Journal
Symmetry Dimension in Obsessive–Compulsive Disorder: Prevalence, Severity and Clinical Correlates
Next Article in Special Issue
Impact of Corticosteroid Administration within 7 Days of the Hospitalization for Influenza Pneumonia with Respiratory Failure: A Propensity Score Analysis Using a Nationwide Administrative Database
Previous Article in Journal
Alterations in Small Intestine and Liver Morphology, Immunolocalization of Leptin, Ghrelin and Nesfatin-1 as Well as Immunoexpression of Tight Junction Proteins in Intestinal Mucosa after Gastrectomy in Rat Model
Review

Favipiravir in Therapy of Viral Infections

1
Department of Conservative Dentistry and Endodontics, Pomeranian Medical University, 70-204 Szczecin, Poland
2
Department of Biochemistry and Medical Chemistry, Pomeranian Medical University, 70-204 Szczecin, Poland
3
Department of Physiology, Pomeranian Medical University, 70-204 Szczecin, Poland
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2021, 10(2), 273; https://doi.org/10.3390/jcm10020273
Received: 12 December 2020 / Revised: 8 January 2021 / Accepted: 9 January 2021 / Published: 13 January 2021
(This article belongs to the Special Issue Virus Infection and Antiviral Drugs)
Favipiravir (FPV) is a novel antiviral drug acting as a competitive inhibitor of RNA-dependent RNA polymerase (RdRp), preventing viral transcription and replication. FPV was approved in Japan in 2014 for therapy of influenza unresponsive to standard antiviral therapies. FPV was also used in the therapy of Ebola virus disease (EVD) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In this review, we discuss the mechanisms of action, pharmacokinetic parameters, toxicity, and adverse effects of FPV, as well as clinical studies evaluating the use of FPV in the therapy of influenza virus (IV) infection, EVD, and SARS-CoV-2 infection, along with its effectiveness in treating other human RNA infections. View Full-Text
Keywords: favipiravir; viral infection; influenza favipiravir; viral infection; influenza
MDPI and ACS Style

Łagocka, R.; Dziedziejko, V.; Kłos, P.; Pawlik, A. Favipiravir in Therapy of Viral Infections. J. Clin. Med. 2021, 10, 273. https://doi.org/10.3390/jcm10020273

AMA Style

Łagocka R, Dziedziejko V, Kłos P, Pawlik A. Favipiravir in Therapy of Viral Infections. Journal of Clinical Medicine. 2021; 10(2):273. https://doi.org/10.3390/jcm10020273

Chicago/Turabian Style

Łagocka, Ryta, Violetta Dziedziejko, Patrycja Kłos, and Andrzej Pawlik. 2021. "Favipiravir in Therapy of Viral Infections" Journal of Clinical Medicine 10, no. 2: 273. https://doi.org/10.3390/jcm10020273

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop